Abstract
African trypanosomes are responsible for sleeping sickness in man and nagana in cattle, which are both tremendous health burdens in Africa. Most African trypanosome species are killed by human serum. This is due to a serum trypanolytic particle specific of some old world monkeys and great apes, an HDL subclass containing two proteins which appeared recently in mammalian evolution, apolipoprotein L1 and haptoglobin related protein. Nevertheless, two African trypanosome species, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense are able to infect humans, because they developed resistance to trypanolysis. Resistance to human serum in Trypanosoma brucei rhodesiense is due to a single gene called SRA. This mechanism of lysis-resistance is therefore an example of a natural drug-antidote system which evolved during a pathogen-host arms race. The lysis and resistance mechanisms, their molecular components as well as their mode of action are reviewed. I also discuss how components of the system would be suitable drug targets and how the system could be engineered to generate an effective synthetic drug.
Keywords: Trypanosoma brucei, trypanosome, apolipoproteinL1, haptoglobin related protein, high density lipoprotein, trypanolysis
Infectious Disorders - Drug Targets
Title: The Human Trypanolytic Factor: A Drug Shaped Naturally
Volume: 10 Issue: 4
Author(s): Luc Vanhamme
Affiliation:
Keywords: Trypanosoma brucei, trypanosome, apolipoproteinL1, haptoglobin related protein, high density lipoprotein, trypanolysis
Abstract: African trypanosomes are responsible for sleeping sickness in man and nagana in cattle, which are both tremendous health burdens in Africa. Most African trypanosome species are killed by human serum. This is due to a serum trypanolytic particle specific of some old world monkeys and great apes, an HDL subclass containing two proteins which appeared recently in mammalian evolution, apolipoprotein L1 and haptoglobin related protein. Nevertheless, two African trypanosome species, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense are able to infect humans, because they developed resistance to trypanolysis. Resistance to human serum in Trypanosoma brucei rhodesiense is due to a single gene called SRA. This mechanism of lysis-resistance is therefore an example of a natural drug-antidote system which evolved during a pathogen-host arms race. The lysis and resistance mechanisms, their molecular components as well as their mode of action are reviewed. I also discuss how components of the system would be suitable drug targets and how the system could be engineered to generate an effective synthetic drug.
Export Options
About this article
Cite this article as:
Vanhamme Luc, The Human Trypanolytic Factor: A Drug Shaped Naturally, Infectious Disorders - Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/187152610791591566
DOI https://dx.doi.org/10.2174/187152610791591566 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Biotransformation of Terpenoids: A Green Alternative for Producing Molecules with Pharmacological Activity
Mini-Reviews in Organic Chemistry Disruptive Nanozyme Technology for Futuristic Bio-Medical and Bio-imaging Applications
Current Nanoscience The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets Infection, its Treatment and the Risk for Stroke
Current Vascular Pharmacology Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Advances in Photodynamic Therapy Assisted by Electroporation
Current Drug Metabolism Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets Synthesis and Biological Evaluation of a Series of 2-(3,4,5-Trimethoxybenzoyl)-Indol-3-yl Acetic Acid Derivatives as Potential Agents against Human Leukemia K562 Cells
Letters in Drug Design & Discovery Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Neonatal Germ Cell Tumors
Current Pediatric Reviews Bioactives in Disease Prevention and Health Promotion: Exploiting Combinatorial Effects
Current Bioactive Compounds Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Contemporary Progress in the Synthetic Strategies of Imidazole and its Biological Activities
Current Organic Synthesis